RU2010134360A - Комбинация слитого белка антитело против edb фибронектина-il-2 и молекулы, связывающейся с в-клетками, предшественниками в-клеток и/или их злокачественным аналогом - Google Patents
Комбинация слитого белка антитело против edb фибронектина-il-2 и молекулы, связывающейся с в-клетками, предшественниками в-клеток и/или их злокачественным аналогом Download PDFInfo
- Publication number
- RU2010134360A RU2010134360A RU2010134360/15A RU2010134360A RU2010134360A RU 2010134360 A RU2010134360 A RU 2010134360A RU 2010134360/15 A RU2010134360/15 A RU 2010134360/15A RU 2010134360 A RU2010134360 A RU 2010134360A RU 2010134360 A RU2010134360 A RU 2010134360A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- combination
- combination according
- cells
- seq
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
Abstract
1. Комбинация, содержащая по меньшей мере ! i) слитый белок, содержащий часть-антитело, специфически распознающую EDb-фибронектин, и часть-интерлейкин-2 и ! ii) молекулу, связывающуюся с B-клетками, предшественниками B-клеток и/или их злокачественным аналогом; или слитый белок, содержащий часть-антитело, специфически распознающую EDb-фибронектин, и часть-интерлейкин-2 и молекулу, специфически связывающуюся с CD20; или ! iii) слитый белок, содержащий часть-антитело, специфически распознающую EDb-фибронектин, и часть-интерлейкин-2 и молекулу, специфически связывающуюся с клетками, экспрессирующими CD20. ! 2. Комбинация по п.1, в которой молекула, связывающаяся с B-клетками, предшественниками B-клеток и/или их злокачественным аналогом, специфически связывается с CD20, CD23, CD22, CD40, CD80, HLA-DR или Hu1D10. ! 3. Комбинация по п.2, в которой молекула, специфически связывающаяся с CD20, CD23, CD22, CD40 или CD80, представляет собой антитело или фрагмент антитела или их слитый белок. ! 4. Комбинация по п.1, в которой слитый белок имеет линкер слитого белка, соединяющий часть-антитело и часть-интерлейкин-2. !5. Комбинация по п.1, в которой часть-антитело специфически связывается с доменом EDb онкоэмбрионального фибронектина с субнаномолярной или наномолярной аффинностью. ! 6. Комбинация по п.1, в которой часть-антитело содержит по меньшей мере одну последовательность CDR антитела L19. ! 7. Комбинация по п.1, в которой часть-антитело содержит последовательности согласно SEQ ID NO: 6-11. ! 8. Комбинация по п.1, в которой часть-антитело содержит по меньшей мере одну тяжелую цепь V согласно SEQ ID NO: 1 или по меньшей мере одну легкую цепь V согласно SEQ ID NO: 2. ! 9. Комбинация по п.1, в которой часть-антите
Claims (30)
1. Комбинация, содержащая по меньшей мере
i) слитый белок, содержащий часть-антитело, специфически распознающую EDb-фибронектин, и часть-интерлейкин-2 и
ii) молекулу, связывающуюся с B-клетками, предшественниками B-клеток и/или их злокачественным аналогом; или слитый белок, содержащий часть-антитело, специфически распознающую EDb-фибронектин, и часть-интерлейкин-2 и молекулу, специфически связывающуюся с CD20; или
iii) слитый белок, содержащий часть-антитело, специфически распознающую EDb-фибронектин, и часть-интерлейкин-2 и молекулу, специфически связывающуюся с клетками, экспрессирующими CD20.
2. Комбинация по п.1, в которой молекула, связывающаяся с B-клетками, предшественниками B-клеток и/или их злокачественным аналогом, специфически связывается с CD20, CD23, CD22, CD40, CD80, HLA-DR или Hu1D10.
3. Комбинация по п.2, в которой молекула, специфически связывающаяся с CD20, CD23, CD22, CD40 или CD80, представляет собой антитело или фрагмент антитела или их слитый белок.
4. Комбинация по п.1, в которой слитый белок имеет линкер слитого белка, соединяющий часть-антитело и часть-интерлейкин-2.
5. Комбинация по п.1, в которой часть-антитело специфически связывается с доменом EDb онкоэмбрионального фибронектина с субнаномолярной или наномолярной аффинностью.
6. Комбинация по п.1, в которой часть-антитело содержит по меньшей мере одну последовательность CDR антитела L19.
7. Комбинация по п.1, в которой часть-антитело содержит последовательности согласно SEQ ID NO: 6-11.
8. Комбинация по п.1, в которой часть-антитело содержит по меньшей мере одну тяжелую цепь V согласно SEQ ID NO: 1 или по меньшей мере одну легкую цепь V согласно SEQ ID NO: 2.
9. Комбинация по п.1, в которой часть-антитело содержит одну тяжелую цепь V согласно SEQ ID NO: 1 и одну легкую цепь V согласно SEQ ID NO: 2.
10. Комбинация по п.1, в которой тяжелая и легкая цепи соединены линкером антитела.
11. Комбинация по п.1, в которой линкер антитела содержит последовательность согласно SEQ ID NO: 3 или последовательность, имеющую по меньшей мере 90% идентичность с последовательностью согласно SEQ ID NO: 3.
12. Комбинация по п.1, в которой часть-интерлейкин-2 представляет собой интерлейкин-2 человека или его функциональный вариант.
13. Комбинация по п.1, в которой часть-интерлейкин-2 содержит последовательность согласно SEQ ID NO: 4.
14. Комбинация по п.1, в которой линкер слитого белка соединяет часть-антитело и часть-интерлейкин-2.
15. Комбинация по п.1, в которой линкер слитого белка имеет от 1 до 30 аминокислот в длину.
16. Комбинация по п.1, в которой линкер слитого белка содержит последовательность согласно SEQ ID NO: 5.
17. Комбинация по п.3, в которой антитело или фрагмент антитела или их слитый белок специфически связывается с CD20.
18. Комбинация по п.17, в которой антитело против CD20 проявляет активность ADCC.
19. Комбинация по п.1, в которой молекула, специфически связывающаяся с CD20, или молекула, специфически связывающаяся с клетками, экспрессирующими CD20, представляет собой антитело или фрагмент антитела.
20. Комбинация по п.19, в которой антитело против CD20 выбрано из ритуксимаба, окрелизумаба, PRO131921, велтузумаба, офатумумаба, AME-133 и GA-101.
21. Комбинация по п.1, в которой молекула, связывающаяся с B-клетками, предшественниками B-клеток и/или их злокачественным аналогом является меченной, в частности радиоактивно меченной.
22. Комбинация по п.21, в которой меченная молекула, связывающаяся с B-клетками, предшественниками B-клеток и/или их злокачественным аналогом, представляет собой радиоактивно меченное антитело против CD20.
23. Комбинация по п.22, в которой радиоактивно меченное антитело против CD20 выбрано из антитела против CD20 меченного 90Y, 111In и 131I.
24. Комбинация по п.23, в которой радиоактивно меченное антитело против CD20 выбрано из Y-90-ибритумомаб-тиуксетана (Y90-Зевалин®) и I-131-тозитумомаба (Бексар®).
25. Комбинация по п.1 для применения в качестве лекарственного препарата.
26. Комбинация по п.25 для применения в качестве лекарственного препарата для лечения злокачественного новообразования.
27. Комбинация по п.26, где злокачественное новообразование представляет собой лимфому.
28. Комбинация по п.27, где лимфома представляет собой B-клеточную лимфому, в частности неходжкинскую лимфому (NHL).
29. Комбинация по п.25 для лечения аутоиммунных заболеваний.
30. Комбинация по п.29, где аутоиммунное заболевание выбрано из ревматоидного артрита, болезни Крона, язвенного колита и аутоиммунной гемолитической анемии.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08075044.1 | 2008-01-17 | ||
EP08075044A EP2085095B1 (en) | 2008-01-17 | 2008-01-17 | Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart |
PCT/EP2008/009441 WO2009089858A1 (en) | 2008-01-17 | 2008-11-08 | COMBINATION OF AN ANTI-EDb FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2010134360A true RU2010134360A (ru) | 2012-02-27 |
RU2484845C2 RU2484845C2 (ru) | 2013-06-20 |
Family
ID=39427510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010134360/15A RU2484845C2 (ru) | 2008-01-17 | 2008-11-08 | КОМБИНАЦИЯ СЛИТОГО БЕЛКА АНТИТЕЛО ПРОТИВ EDb ФИБРОНЕКТИНА-IL-2 И МОЛЕКУЛЫ, СВЯЗЫВАЮЩЕЙСЯ С В-КЛЕТКАМИ, ПРЕДШЕСТВЕННИКАМИ В-КЛЕТОК И/ИЛИ ИХ ЗЛОКАЧЕСТВЕННЫМ АНАЛОГОМ |
Country Status (13)
Country | Link |
---|---|
US (3) | US20100310454A1 (ru) |
EP (1) | EP2085095B1 (ru) |
JP (1) | JP5140164B2 (ru) |
KR (1) | KR20100113572A (ru) |
CN (1) | CN101969980A (ru) |
AT (1) | ATE548052T1 (ru) |
AU (1) | AU2008347450B2 (ru) |
BR (1) | BRPI0822044A2 (ru) |
CA (1) | CA2711902C (ru) |
ES (1) | ES2382058T3 (ru) |
MX (1) | MX2010007716A (ru) |
RU (1) | RU2484845C2 (ru) |
WO (1) | WO2009089858A1 (ru) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2382058T3 (es) | 2008-01-17 | 2012-06-04 | Philogen S.P.A. | Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos |
AU2009336800A1 (en) * | 2009-01-07 | 2011-07-21 | Philogen S.P.A. | Cancer treatment |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
US20120258073A1 (en) * | 2011-02-10 | 2012-10-11 | Christian Gerdes | Immunotherapy |
SI2673294T1 (sl) | 2011-02-10 | 2016-08-31 | Roche Glycart Ag | Mutirani polipeptidi interlevkina-2 |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
US20190002516A1 (en) * | 2015-12-21 | 2019-01-03 | Hefei Lifeon Pharmaceutical Co., Ltd. | Drug Design Method, Obtained Drug and Application Thereof |
GB201621806D0 (en) | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
US12006354B2 (en) | 2017-05-24 | 2024-06-11 | Novartis Ag | Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer |
EP3660039A1 (en) | 2018-11-30 | 2020-06-03 | Philogen S.p.A. | Il2 immunoconjugates |
WO2020070150A1 (en) | 2018-10-02 | 2020-04-09 | Philogen S.P.A | Il2 immunoconjugates |
WO2020249757A1 (en) | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha |
KR102614063B1 (ko) | 2020-12-24 | 2023-12-19 | 대화제약 주식회사 | 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체 |
WO2023180409A1 (en) * | 2022-03-23 | 2023-09-28 | Philogen S.P.A | Il2 immunoconjuqate preparation |
WO2024047237A1 (en) | 2022-09-01 | 2024-03-07 | Philogen S.P.A. | Tnf alpha and interleukin-2 combination therapy for non-melanoma skin cancer |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI82266C (fi) | 1982-10-19 | 1991-02-11 | Cetus Corp | Foerfarande foer framstaellning av il-2 -mutein. |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
WO1985000817A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
US5243029A (en) * | 1986-04-09 | 1993-09-07 | Fred Hutchinson Cancer Research Center | Oncofetal structure of fibronectin |
ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
WO1992015682A1 (en) | 1991-02-27 | 1992-09-17 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
CA2126967A1 (en) | 1992-11-04 | 1994-05-11 | Anna M. Wu | Novel antibody construct |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
MD1367C2 (ru) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Методы лечения лимфомы В-клеток, антитела анти-CD20, гибридома. |
ES2434840T3 (es) | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
ATE230277T1 (de) | 1997-06-13 | 2003-01-15 | Genentech Inc | Stabilisierte antikörperformulierung |
TWI259837B (en) | 1998-05-11 | 2006-08-11 | Eidgenossische Tech Hochscule | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
US20030176663A1 (en) * | 1998-05-11 | 2003-09-18 | Eidgenossische Technische Hochscule | Specific binding molecules for scintigraphy |
US20030045681A1 (en) * | 1998-05-11 | 2003-03-06 | Anthony J. Zelano | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
PT1719528E (pt) * | 2000-02-24 | 2012-01-06 | Philogen Spa | Composições e métodos para tratamento de angiogénese em lesões patológicas |
JP2004529848A (ja) * | 2000-09-07 | 2004-09-30 | シエーリング アクチエンゲゼルシャフト | EDb−フィブロネクチンドメイン(II)の受容体 |
EP1463524A4 (en) * | 2001-12-07 | 2005-02-09 | Chiron Corp | THERAPEUTIC METHODS FOR TREATING NON-HODGKINIAN LYMPHOMA |
WO2003076469A2 (en) | 2002-03-11 | 2003-09-18 | Philogen S.P.A. | Antibodies derived rom anti ed-b l19 and targeting tumor vasculature |
EP1514561A1 (en) * | 2003-09-10 | 2005-03-16 | Philogen S.p.A. | Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B |
BRPI0607351A2 (pt) * | 2005-02-15 | 2009-09-01 | Novartis Vaccines & Diagnostic | métodos para tratamento de linfomas empregando uma combinação de agente quimioterapêutico e il-2 e opcionalmente um anticorpo anti-cd20 |
EP1842553A1 (en) * | 2006-04-07 | 2007-10-10 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule |
EP2036576A1 (en) * | 2007-09-17 | 2009-03-18 | Bayer Schering Pharma Aktiengesellschaft | ED-B fibronectin as stratification marker for antitumor drugs |
ES2382058T3 (es) | 2008-01-17 | 2012-06-04 | Philogen S.P.A. | Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos |
-
2008
- 2008-01-17 ES ES08075044T patent/ES2382058T3/es active Active
- 2008-01-17 EP EP08075044A patent/EP2085095B1/en not_active Not-in-force
- 2008-01-17 AT AT08075044T patent/ATE548052T1/de active
- 2008-11-08 AU AU2008347450A patent/AU2008347450B2/en not_active Ceased
- 2008-11-08 WO PCT/EP2008/009441 patent/WO2009089858A1/en active Application Filing
- 2008-11-08 RU RU2010134360/15A patent/RU2484845C2/ru not_active IP Right Cessation
- 2008-11-08 CA CA2711902A patent/CA2711902C/en not_active Expired - Fee Related
- 2008-11-08 US US12/863,417 patent/US20100310454A1/en not_active Abandoned
- 2008-11-08 KR KR1020107018174A patent/KR20100113572A/ko not_active Application Discontinuation
- 2008-11-08 MX MX2010007716A patent/MX2010007716A/es active IP Right Grant
- 2008-11-08 CN CN2008801249387A patent/CN101969980A/zh active Pending
- 2008-11-08 BR BRPI0822044-1A patent/BRPI0822044A2/pt not_active IP Right Cessation
- 2008-11-08 JP JP2010542524A patent/JP5140164B2/ja not_active Expired - Fee Related
- 2008-11-13 US US12/270,174 patent/US8796426B2/en not_active Expired - Fee Related
-
2014
- 2014-06-17 US US14/306,992 patent/US9289470B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2011509953A (ja) | 2011-03-31 |
EP2085095A1 (en) | 2009-08-05 |
US20090202473A1 (en) | 2009-08-13 |
JP5140164B2 (ja) | 2013-02-06 |
RU2484845C2 (ru) | 2013-06-20 |
ES2382058T3 (es) | 2012-06-04 |
CN101969980A (zh) | 2011-02-09 |
WO2009089858A1 (en) | 2009-07-23 |
ATE548052T1 (de) | 2012-03-15 |
EP2085095B1 (en) | 2012-03-07 |
AU2008347450A1 (en) | 2009-07-23 |
KR20100113572A (ko) | 2010-10-21 |
US8796426B2 (en) | 2014-08-05 |
US9289470B2 (en) | 2016-03-22 |
CA2711902A1 (en) | 2009-07-23 |
US20100310454A1 (en) | 2010-12-09 |
AU2008347450B2 (en) | 2013-07-25 |
BRPI0822044A2 (pt) | 2015-07-28 |
US20140294723A1 (en) | 2014-10-02 |
CA2711902C (en) | 2017-07-18 |
MX2010007716A (es) | 2010-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2010134360A (ru) | Комбинация слитого белка антитело против edb фибронектина-il-2 и молекулы, связывающейся с в-клетками, предшественниками в-клеток и/или их злокачественным аналогом | |
JP2011509953A5 (ru) | ||
CA2953992C (en) | Bispecific cd33 and cd3 binding proteins | |
FI2995315T3 (fi) | Koostumuksia ja menetelmiä hematologisten syöpien hoitamiseksi kohdistuen sirp-alfan ja cd47:n interaktioon | |
US20180208657A1 (en) | Recombinant antibody molecule and its use for target cell restricted t cell activation | |
EP3929212A1 (en) | Modified fc fragment, antibody comprising same, and application thereof | |
TWI771316B (zh) | 條件性活性多肽及產生其之方法 | |
EA201100228A1 (ru) | Структурные варианты антител для улучшения терапевтических характеристик | |
WO2016142314A1 (en) | FUSION PROTEINS COMPRISING A BINDING PROTEIN AND AN INTERLEUKIN-15 POLYPEPTIDE HAVING A REDUCED AFFINITY FOR IL15Ra AND THERAPEUTIC USES THEREOF | |
RU2017134652A (ru) | Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) k cd19 | |
JP7359700B2 (ja) | Cd38抗体薬物コンジュゲート | |
MX2009003838A (es) | Anticuerpos anti-cd20 y metodos de uso. | |
Matlawska-Wasowska et al. | Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies | |
NZ705848A (en) | Anti-cd38 antibodies | |
PE20060817A1 (es) | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina | |
NZ623319A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
RU2014109039A (ru) | Биспецифические антигенсвязывающие молекулы | |
PE20081171A1 (es) | Nuevos anticuerpos anti-cd38 para el tratamiento del cancer | |
BRPI0515604A (pt) | método para o tratamento de células de cáncer e método de tratamento de uma doença imune relacionada | |
CA3206529A1 (en) | Heterotandem bicyclic peptide complexes | |
Mayes et al. | New antibody drug treatments for lymphoma | |
Safdari et al. | CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies | |
EP4313312A1 (en) | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging | |
KR20210043582A (ko) | 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법 | |
JP2021506260A (ja) | 抗cct5結合分子およびその使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20201109 |